Nobivac Feline 1-HCP+FeLV Vaccine

Supplied By: Merck (065265)


SKU
009456


Unit of
Measure 25 x 1 Dose


Pack
Type Box


Case
Qty 1

Login
{{promo.PromoName}}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}
Dec- 2024 Nov- 2024 Oct- 2024 Sep- 2024 Aug- 2024 Jul- 2024 Jun- 2024 May- 2024 Apr- 2024 Mar- 2024 Feb- 2024 Jan- 2024 Dec- 2023
{{purchaseHistoryItem}}


SKU 009456


Size 25 x 1 Dose

Case
Qty 1

Purchase History

Dec- 2024 {{productPurchaseHistory['009456'][0]}} May- 2024 {{productPurchaseHistory['009456'][0+7]}}
Nov- 2024 {{productPurchaseHistory['009456'][1]}} Apr- 2024 {{productPurchaseHistory['009456'][1+7]}}
Oct- 2024 {{productPurchaseHistory['009456'][2]}} Mar- 2024 {{productPurchaseHistory['009456'][2+7]}}
Sep- 2024 {{productPurchaseHistory['009456'][3]}} Feb- 2024 {{productPurchaseHistory['009456'][3+7]}}
Aug- 2024 {{productPurchaseHistory['009456'][4]}} Jan- 2024 {{productPurchaseHistory['009456'][4+7]}}
Jul- 2024 {{productPurchaseHistory['009456'][5]}} Dec- 2023 {{productPurchaseHistory['009456'][5+7]}}
Jun- 2024 {{productPurchaseHistory['009456'][6]}}
{{promo.PromoName }}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}
Login

Compare Products

{{compareProd.sku}}

{{compareProd.desc}}

{{compareMessage}}

Product Description

For the vaccination of healthy cats as an aid in the prevention of disease caused by feline rhinotracheitis, calici, panleukopenia and feline leukemia.

Features & Benefits

  • A quality core vaccine that protects against feline rhinotracheitis, feline panleukopenia virus (FPV), and feline calicivirus (FCV), in addition to providing extensive 2-year coverage for FeLV
  • Nobivac® Feline 1-HCP has been shown to block the replication of canine parvovirus (CPV) in cats
  • Evidence shows that CPV-2a, CPV-2b, and CPV-2c isolates can replicate in cats, producing clinical signs of feline panleukopenia
  • The only feline leukemia vaccine labeled to prevent persistent viremia for 2 years after vaccination
  • 96% of vaccinated cats were protected against persistent viremia after FeLV challenge
  • In a 2-year study involving 23 FeLV-negative cats:
  • After 12 weeks, 83% of vaccinates were free of persistent and transient viremia
  • All 11 control cats (100%) developed persistent viremia
  • Results showed that cats developed immunity solely through the initial vaccination series
  • Optimal choice for both indoor and outdoor cats